TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31658994
Drug: Ipilimumab with
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab with concurrent stereotactic radiation therapy (50 Gy in 4 fractions or 60 Gy in 10 fractions)
Study: 31658994
Drug: Ipilimumab with
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab with sequential stereotactic radiation therapy
Study: 31658994
Drug: Ipilimumab with
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab with concurrent stereotactic radiation therapy
Study: 31658994
Drug: Ipilimumab with
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab with stereotactic radiation therapy (sequential lung group)
Study: 31658994
Drug: Low-dose radiation
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose radiation to nontargeted lesions
Study: 26520894
Drug: Mesoglycan (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesoglycan (60 mg, single i.m. administration)
Study: 14695722
Drug: Nefopam at
Normalized name: nefopam
DrugBank: Nefopam (DB12293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam at a target plasma concentration of 70 ng/ml (high dose, approximately 20 mg total)
Study: 14695722
Drug: Nefopam at
Normalized name: nefopam
DrugBank: Nefopam (DB12293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam at a target plasma concentration of 35 ng/ml (low dose)
Study: 3033593
Drug: 10(4) PFU
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10(4) PFU of vaccine virus
Study: 24511715
Drug: Sublingual 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual 200 microg of misoprostol
Study: 16409513
Drug: Coca-Cola treatment
Normalized name: cola extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coca-Cola treatment for 2 hours
Study: 16409513
Drug: Coca-Cola treatment
Normalized name: cola extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coca-Cola treatment for 3 hours
Study: 12942586
Drug: 7 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 g/day of inulin
Study: 7506400
Drug: Argon laser
Normalized name: argon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argon laser photocoagulation treatment
Study: 483364
Drug: Levamisole 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole 2.5 mg/kg of body weight (90% coverage)
Study: 483364
Drug: Levamisole 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole 2.5 mg/kg of body weight (60% coverage)
Study: 483364
Drug: Levamisole 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole 2.5 mg/kg of body weight (40% coverage)
Study: 28666680
Drug: Inactivated influenza
Normalized name: influenza, inactivated, whole virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated influenza vaccine by self-administered microneedle patch
Study: 11819768
Drug: Omeprazole 2
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 2 X 20mg, clarithromycin 2 X 500mg, and amoxicillin 2 X 1g for 7 days
Study: 8866631
Drug: Prazosin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (1 mg)
Study: 1071692
Drug: Hydrallazine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrallazine (20 mg)
Study: 24125402
Drug: simvastatin/ezetimibe 10/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: simvastatin/ezetimibe 10/10 mg
Study: 17176348
Drug: Injection practices
Normalized name: Practical Alchemy Purify and Protect Duo KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection practices assessment
Study: 3139179
Drug: Tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg twice daily
Study: 2411103
Drug: Topical nasal
Normalized name: Nasal Inhalant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nasal decongestants
Study: 25524791
Drug: Systematic stimulant
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic stimulant treatment
Study: 14513417
Drug: 5-drug salvage
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-drug salvage regimen after 12 weeks of structured treatment interruption (STI)
Study: 14513417
Drug: 5-drug salvage
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-drug salvage regimen immediately (noninterruption [NI] group])
Study: 10846380
Drug: Midazolam lollipop
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam lollipop (5 mg)
Study: 10846380
Drug: Midazolam and
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam and atropine lollipop (5 mg midazolam and 0.25 mg atropine)
Study: 3436155
Drug: Indomod (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomod (75 mg sustained-release indomethacin)
Study: 3436155
Drug: Indocid R
Normalized name: Indocid R
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indocid R (25 mg normal, 50 mg sustained-release indomethacin)
Study: 18157013
Drug: Cytokine-induced killer
Normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cytokine-induced killer (CIK) cells therapy
Study: 16979496
Drug: Single low-level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single low-level laser therapy (LLLT); Mini Laser 2075, Helbo Photodynamic Systems GmbH & Co KG, Linz, Austria; wavelength 670 nm, power output 75 mW; duration 30 seconds per banded tooth
Study: 16979496
Drug: Placebo laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo laser therapy without active laser irradiation
Study: 10930199
Drug: Lactated Ringer's
Normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer's solution (LR) 1 L
Study: 31531854
Drug: Fentanyl intravenous
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl intravenous patient-controlled analgesia
Study: 22068809
Drug: combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination of both
Study: 30465369
Drug: Haemocoel preload
Normalized name: Haemaccel
DrugBank: Polygeline (DB15879)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haemocoel preload (500 ml before spinal anaesthesia)
Study: 26762672
Drug: PR-fampridine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: PR-fampridine (10 mg, twice daily)
Study: 22426704
Drug: Spinal exercise
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal exercise therapy and analgesics (Control group)
Study: 18356664
Drug: 4 peritumoral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 peritumoral (PT) injections
Study: 18356664
Drug: PT and
Normalized name: ZINC OXIDE 165 mg in 1 g TOPICAL STICK [Ciele Sculpt and Protect]
Approvals — FDA: no, EMA: no, PMDA: no
Description: PT and SD injection groups
Study: 10482007
Drug: Clobetasol-17 propionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobetasol-17 propionate lotion under hydrocolloid dressing (Duoderm ET) once weekly
Study: 10482007
Drug: Clobetasol-17 propionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobetasol-17 propionate ointment without an HCD twice daily
Study: 6238338
Drug: 70 mg
Normalized name: silybin 70 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 mg paroxetine
Study: 31295048
Drug: Women who
Normalized name: Arthricare for Women Moisturizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women who received ≥1 dose of HPV vaccine
Study: 31295048
Drug: Women who
Normalized name: Arthricare for Women Moisturizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women who did not receive HPV vaccine (unvaccinated)
Study: 12466341
Drug: Fluvastatin XL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin XL 80 mg
Study: 10703470
Drug: 12 G
Normalized name: PEG-12 GLYCERYL LAURATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 G needle
Study: 1897688
Drug: L-648,051 (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-648,051 (800 micrograms) inhaled during the immediate phase (15 min after antigen challenge)
Study: 1897688
Drug: L-648,051 (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-648,051 (800 micrograms) inhaled before antigen challenge (5 min before)
Study: 28542611
Drug: ZIKV testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZIKV testing (plasma samples for ZIKV nucleic acid and antibodies)
Study: 24825530
Drug: Dexamethasone 40
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 40 mg (D40)
Study: 24825530
Drug: Dexamethasone 8
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 8 mg (D8)
Study: 17440005
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (deactivation of ICD therapies for AT/AF)
Study: 20637970
Drug: Avanafil 100
Normalized name: avanafil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avanafil 100 mg
Study: 26037035
Drug: Intradermal (ID)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal (ID) bolus infusion of insulin aspart (NovoRapid U-100)
Study: 20920848
Drug: Three-times daily
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Three-times daily tobramycin and ceftazidime
Study: 19100416
Drug: Tripterygium wilfordii
Normalized name: TRIPTERYGIUM WILFORDII ROOT
DrugBank: Tripterygium wilfordii whole (DB14277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tripterygium wilfordii (T II) 1 mg/kg/d for 12 months
Study: 8793604
Drug: Pantoprazole 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 30 mg i.v. (acute study)
Study: 6432172
Drug: Omeprazole 30
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole 30 mg
Study: 15109187
Drug: Omeprazole 60
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole 60 mg
Study: 20105039
Drug: Combination (C)
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination (C) wave
Study: 20105039
Drug: Modified Combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Combination (MC) wave
Study: 17622884
Drug: Oral fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral fluconazole (400 mg loading dose followed by 200 mg QD for one week)
Study: 11995262
Drug: Montelukast (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (5 or 10 mg according to age)
Study: 12053590
Drug: Nedocromil (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nedocromil (16 mg)
Study: 2196121
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (aminoglycoside, amoxicillin, clindamycin)
Study: 372823
Drug: Poly I:C
Normalized name: poly I:C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poly I:C immunotherapy
Study: 26188923
Drug: Vascular medicine
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vascular medicine physicians (VMP) managing iDDVT
Study: 26188923
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of iDDVT as long as proximal DVT by GP
Study: 26188923
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of iDDVT by VMP
Study: 16358612
Drug: New treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: New treatment protocol for heart failure patients in general practice, based on many RCT's and reviews.
Study: 16358612
Drug: Co- and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co- and multi-medication in frail elderly patients.
Study: 753026
Drug: Estramustine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estramustine and prednimustine combination
Study: 24158326
Drug: Electrostimulator (ES)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrostimulator (ES) technique with 0.2 ml/kg (E1)
Study: 24158326
Drug: Electrostimulator (ES)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrostimulator (ES) technique with 0.6 ml/kg (E2)
Study: 24158326
Drug: Electrostimulator (ES)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrostimulator (ES) technique with 1.0 ml/kg (E3)
Study: 24158326
Drug: Blinded technique
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinded technique with 1.0 ml/kg (B4)
Study: 21707914
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group without cell therapy
Study: 19012356
Drug: Celecoxib 3
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib 3 mg/kg bid
Study: 19012356
Drug: Celecoxib 6
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib 6 mg/kg bid
Study: 19012356
Drug: Naproxen 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 7.5 mg/kg bid
Study: 29766891
Drug: Continuous heparin
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous heparin infusion
Study: 11554015
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no heparin infusion)
Study: 8148280
Drug: 5.0 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 mg/kg/day CyA
Study: 8148280
Drug: 2.5 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/kg/day CyA
Study: 8148280
Drug: CyA (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: CyA (both doses)
Study: 30044938
Drug: BCX7353 125
Normalized name: BCX7353
DrugBank: Berotralstat (DB15982)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: BCX7353 125 mg
Study: 23748750
Drug: Ticagrelor 400
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 400 mg qd
Study: 23748750
Drug: Digoxin (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin (0.25 mg bid on day 6 and 0.25 mg qd on days 7-14)
Study: 23748750
Drug: Ticagrelor and
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor and digoxin co-administration
Study: 19099634
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose thalidomide (HD-T)
Study: 19099634
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose thalidomide (LD-T)
Study: 19099634
Drug: Conventional VAD
Normalized name: VAD-044
DrugBank: VAD-044 (DB17697)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional VAD chemotherapy
Study: 9595974
Drug: IVIG 1
Normalized name: Intravenous immunoglobulin (IVIg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG 1 g/kg daily for 2 consecutive days every month for 6 months
Study: 8015122
Drug: Concealment of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concealment of assignment until treatment allocation
Study: 2853751
Drug: Yohimbine infusion
Normalized name: YOHIMBINE
DrugBank: Yohimbine (DB01392)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine infusion (3 micrograms/kg per min) during glucose infusion (20 min) in group I
Study: 27943089
Drug: Diltiazem co-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem co-treatment with microemulsified cyclosporine-A (CsA)
Study: 21167116
Drug: Trivalent seasonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent seasonal influenza vaccine
Study: 22472791
Drug: 7.5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 μg antigen with a full (9.75 mg) adjuvant dose
Study: 22472791
Drug: 3.75 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 μg antigen with a half (4.875 mg) adjuvant dose
Study: 18258801
Drug: Hypoglycemia (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycemia (mean nadir plasma glucose 2.7 +/- 0.5 mmol/l)
Study: 15930210
Drug: Dopamine (DP)
DrugBank: Dopamine (DB00988)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dopamine (DP) at doses of 2.5, 5, 7.5, or 10 microg/kg per minute; n = 28
Study: 15930210
Drug: Epinephrine (EP)
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine (EP) at doses of 0.125, 0.250, 0.375, or 0.5 microg/kg per minute; n = 32
Study: 8894955
Drug: Brief cognitive-behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief cognitive-behaviour therapy (CBT)
Study: 31662354
Drug: Marketing authorisation
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marketing authorisation withdrawal or suspension
Study: 29578578
Drug: Sirukumab 50
Normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirukumab 50 mg every 4 weeks
Study: 19384220
Drug: Daily bathing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily bathing with chlorhexidine solution
Study: 15345983
Drug: Less Invasive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less Invasive Stabilization System (L.I.S.S.) plating
Study: 15345983
Drug: L.I.S.S plate
Approvals — FDA: no, EMA: no, PMDA: no
Description: L.I.S.S plate
Study: 18697778
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment for lower TJC patients
Study: 18697778
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment for higher TJC patients
Study: 18697778
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment for lower SJC patients
Study: 18697778
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment for higher SJC patients
Study: 16860176
Drug: Transdermal buprenorphine
Normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Transdermal buprenorphine 35 microg/h
Study: 9102740
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg once daily for 2 weeks
Study: 31055857
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein (1 g/kg body weight)
Study: 12681528
Drug: GHB (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHB (50 mg/kg t.i.d for 3 months)
Study: 8824652
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg ranitidine b.d.
Study: 1358235
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg ranitidine q.d.s.
Study: 2491468
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg ranitidine nocte
Study: 3714083
Drug: Thyropramide (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyropramide (300 mg per diem for 3 days per os)
Study: 23275364
Drug: n-3 PUFA
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFA supplementation (4 g/day)
Study: 18201206
Drug: Rosiglitazone (RSG)
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rosiglitazone (RSG) 4 mg + Glimepiride (GLIM) 3 mg
Study: 18201206
Drug: Rosiglitazone (RSG)
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rosiglitazone (RSG) 8 mg + Glimepiride (GLIM) 3 mg
Study: 18201206
Drug: Placebo (PBO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PBO) + Glimepiride (GLIM) 3 mg
Study: 18201206
Drug: Rosiglitazone (RSG)
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rosiglitazone (RSG) 4 mg + Glimepiride (GLIM) (low-dose prior to uptitration)
Study: 18201206
Drug: Glimepiride (GLIM)
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glimepiride (GLIM) monotherapy
Study: 21324094
Drug: Gepirone-ER (20-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gepirone-ER (20-80 mg/day)
Study: 11487258
Drug: Anastrozole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole (1 mg o.d.)
Study: 11487258
Drug: Tamoxifen (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (20 mg o.d.)
Study: 11487258
Drug: Anastrozole and
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anastrozole and Tamoxifen (1 mg and 20 mg o.d. respectively)
Study: 16463847
Drug: Acetazolamide (ACZ)
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetazolamide (ACZ) administration
Study: 3140862
Drug: nalmefene 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: nalmefene 0.4 mg/70 kg
Study: 30157896
Drug: 3 monthly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 3 monthly ART supply through community ART groups (CAGs)
Study: 30157896
Drug: 6 monthly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 6 monthly ART supply through community ART distribution points (CAD)
Study: 20618595
Drug: Stretching exercise
Normalized name: Mederma Stretch Mark Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stretching exercise (daily from 18 weeks of gestation to the end of pregnancy)
Study: 14645935
Drug: Active nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active nicotine patches
Study: 7468948
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg terbutaline sulphate aerosol via a 10 cm tube extension
Study: 7468948
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg salbutamol sulphate via conventional pressurized aerosol
Study: 25989606
Drug: 5 mg/day
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/day memantine (MMT+M)
Study: 24604528
Drug: Fit2Quit intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fit2Quit intervention (10 exercise telephone counseling sessions over 6 months) plus usual care (behavioral counseling and nicotine replacement therapy)